HOXA-AS2

Summary

HOXA-AS2 (HOXA cluster antisense RNA 2, HGNC:43745) is a long non-coding RNA gene on chromosome 7p15.2.

This gene produces a long non-coding RNA that promotes cell proliferation. This transcript may interact with enhancer of zeste homolog 2 Polycomb repressive complex to repress gene expression.

Source: NCBI Gene 285943 — RefSeq curated summary.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:43745
Approved symbol	HOXA-AS2
Name	HOXA cluster antisense RNA 2
Location	7p15.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	HOXA3as
Ensembl gene	ENSG00000253552
Ensembl biotype	lncRNA
OMIM	616068
Entrez	285943
RNAcentral	URS000075A2B6 — lncRNA, 1048 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 13 lncRNA

ENST00000517550, ENST00000517635, ENST00000517641, ENST00000518046, ENST00000518088, ENST00000521159, ENST00000521687, ENST00000522193, ENST00000523364, ENST00000524048, ENST00000593438, ENST00000658768, ENST00000669815

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000517550 — 4 exons

Exon	Start	End
ENSE00002138340	27121917	27122026
ENSE00002361398	27123460	27124610
ENSE00002363606	27122467	27122666
ENSE00002375633	27128200	27128760

Expression profiles

Bgee: expression breadth ubiquitous, 155 present calls, max score 96.95.

FANTOM5 (CAGE): breadth broad, TPM avg 1.7384 / max 98.5851, expressed in 599 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
77790	0.5946	348
77791	0.5763	322
77795	0.1183	53
77794	0.0977	50
77797	0.0971	38
77792	0.0953	35
77793	0.0939	43
77796	0.0449	18
77798	0.0161	9
204395	0.0043	3

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	96.95	gold quality
metanephros cortex	UBERON:0010533	92.87	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.47	gold quality
lower esophagus	UBERON:0013473	90.46	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.07	gold quality
esophagus	UBERON:0001043	89.13	gold quality
descending thoracic aorta	UBERON:0002345	88.93	gold quality
esophagus mucosa	UBERON:0002469	88.65	gold quality
left uterine tube	UBERON:0001303	87.98	gold quality
lower esophagus mucosa	UBERON:0035834	87.63	gold quality
mucosa of stomach	UBERON:0001199	87.17	gold quality
thoracic aorta	UBERON:0001515	85.43	gold quality
ascending aorta	UBERON:0001496	85.20	gold quality
muscle layer of sigmoid colon	UBERON:0035805	84.07	gold quality
right lung	UBERON:0002167	83.99	gold quality
transverse colon	UBERON:0001157	83.29	gold quality
omental fat pad	UBERON:0010414	82.90	gold quality
peritoneum	UBERON:0002358	82.83	gold quality
left adrenal gland cortex	UBERON:0035825	82.22	gold quality
small intestine Peyer’s patch	UBERON:0003454	81.91	gold quality
upper lobe of left lung	UBERON:0008952	81.76	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.63	gold quality
left adrenal gland	UBERON:0001234	81.59	gold quality
adult mammalian kidney	UBERON:0000082	81.22	gold quality
right adrenal gland	UBERON:0001233	81.11	gold quality
fallopian tube	UBERON:0003889	81.07	gold quality
rectum	UBERON:0001052	80.96	gold quality
mucosa of transverse colon	UBERON:0004991	80.72	gold quality
adipose tissue of abdominal region	UBERON:0007808	80.60	gold quality
adrenal tissue	UBERON:0018303	80.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.55

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 33)

• the inhibition of HOXA-AS2 in hepatocellular carcinoma significantly inhibited cell proliferation in vitro and in vivo. (PMID:27855366)
• HOXA-AS2 overexpression significantly promoted GBC cell migration and invasion by promoting EMT. Taken together, our study demonstrates that HOXA-AS2 could act as a functional oncogene in GBC, as well as a potential therapeutic target to inhibit GBC metastasis. (PMID:28388535)
• HOXA-AS2 could negatively regulate the expression of miR-520c-3p in osteosarcoma cells. (PMID:30081707)
• the present study revealed that HOXA-AS2 functions as an oncogene in PTC and promotes progression of this disease by acting as a ceRNA, sponging miR-15a-5p, and regulating HOXA3. (PMID:30375256)
• HOXA-AS2 promotes tumor progression of PTC in vitro and in vivo is mediated by inhibiting miR-520c-3p expression, thus, influenced downstream genes S100A4 expression. (PMID:30384358)
• this study also identified miR-125b as a downstream target of HOXA-AS2 and revealed the downregulation of miR-125b by HOXA-AS2 as well as the involvement of HOXA-AS2/miR-125b/Smad2 interactions in the functional role of HOXA-AS2 in mediating the migration, invasion and stemness of bladder cancer cells (PMID:30412716)
• HOXA-AS2 knockdown significantly inhibited hepatocellular carcinoma cells proliferation by causing G1 arrest and promoting apoptosis, whereas HOXA-AS2 overexpression promoted cell growth. HOXA-AS2 could positively regulate GPC3 expression through modulation of miR-520c-3p in hepatocellular carcinoma cells. (PMID:30415263)
• Knockdown of HOXA-AS2 inhibited ADR cell proliferation and apoptosis via miR-520c-3p at 3’-UTR with complementary binding sites. (PMID:30466095)
• HOXA-AS2 enhanced glucocorticoid resistance in acute lymphoblastic leukemia via promoting cell proliferation and inhibiting cell apoptosis. (PMID:30551418)
• HOXA-AS2 functions as a critical repressor of endothelium inflammation by regulating the activity of NF-kappaB signaling. (PMID:30658190)
• Long noncoding RNA HOXA-AS2 regulates the expression of SCN3A by sponging miR-106a in breast cancer. (PMID:30993766)
• Long noncoding RNA HOXA-AS2 promotes cell migration and invasion via upregulating IGF-2 in non-small cell lung cancer as an oncogene. (PMID:31210310)
• LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer. (PMID:31389597)
• LncRNA HOXA-AS2 accelerates the proliferation and migration and inhibits the apoptosis of vascular smooth muscle cells by absorbing miRNA-877-3p. (PMID:31957850)
• Upregulated level of lncRNA HOXA-AS2 in peripheral blood of systemic lupus erythematosus patients aggravates disease progression via ERK pathway. (PMID:32030967)
• Long noncoding RNA HOXA-AS2 mediates microRNA-106b-5p to repress sepsis-engendered acute kidney injury. (PMID:32048402)
• Genome-wide screening of functional long noncoding RNAs in the epicardial adipose tissues of atrial fibrillation. (PMID:32147422)
• Overexpression of long noncoding RNA HOXA-AS2 predicts an adverse prognosis and promotes tumorigenesis via SOX4/PI3K/AKT pathway in acute myeloid leukemia. (PMID:32369230)
• LncRNA HOXA-AS2 promotes the progression of prostate cancer via targeting miR-509-3p/PBX3 axis. (PMID:32519740)
• Microarray Analysis of Long Non-Coding RNAs in Lung Tissues of Patients with COPD and HOXA-AS2 Promotes HPMECs Proliferation via Notch1. (PMID:33116460)
• Overexpression of HOXA-AS2 LncRNA in Patients with Gastric Cancer and Its Association with Helicobacter pylori Infection. (PMID:33174119)
• Long noncoding RNA HOXA-AS2 functions as an oncogene by binding to EZH2 and suppressing LATS2 in acute myeloid leukemia (AML). (PMID:33268767)
• ARID1B/SUB1-activated lncRNA HOXA-AS2 drives the malignant behaviour of hepatoblastoma through regulation of HOXA3. (PMID:33683826)
• LncRNA HOXA-AS2 Activates the Notch Pathway to Promote Cervical Cancer Cell Proliferation and Migration. (PMID:34076871)
• LncRNA HOXA-AS2 regulates microglial polarization via recruitment of PRC2 and epigenetic modification of PGC-1alpha expression. (PMID:34511122)
• LncRNA HOXA-AS2 Promotes Oral Squamous Cell Proliferation, Migration, and Invasion via Upregulating EZH2 as an Oncogene. (PMID:34519570)
• HOXA-AS2 contributes to regulatory T cell proliferation and immune tolerance in glioma through the miR-302a/KDM2A/JAG1 axis. (PMID:35181676)
• The Long Non-Coding RNA HOXA-AS2 Promotes Proliferation of Glioma Stem Cells and Modulates Their Inflammation Pathway Mainly through Post-Transcriptional Regulation. (PMID:35563134)
• HOXA cluster antisense RNA 2 elevates KIAA1522 expression through microRNA-520d-3p and insulin like growth factor 2 mRNA binding protein 3 to promote the growth of vascular smooth muscle cells in thoracic aortic aneurysm. (PMID:35730141)
• Long Noncoding RNA HOXA-AS2 Facilitates Prostate Cancer Progression by Inhibiting miR-885-5p to Upregulate KDM5B. (PMID:36404720)
• LncRNA HOXA-AS2 Promotes Temozolomide Resistance in Glioblastoma by Regulated miR-302a-3p/IGF1 Axis. (PMID:36479381)
• Overexpression of lncRNA HOXA-AS2 promotes the progression of oral squamous cell carcinoma by mediating SNX5 expression. (PMID:36528556)
• HOXA-AS2 Epigenetically Inhibits HBV Transcription by Recruiting the MTA1-HDAC1/2 Deacetylase Complex to cccDNA Minichromosome. (PMID:38647380)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.